Table 2 Patient characteristics of men diagnosed with non-metastatic prostate cancer stratified by the Cambridge Prognostic Group (CPG)
CPG1 | CPG2 | CPG3 | CPG4 | CPG5 | All men | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | |
Age group (years) | ||||||||||||
< 60 | 2637 | 24.1 | 2627 | 19.3 | 1052 | 11.1 | 1553 | 12.1 | 1118 | 7.4 | 8987 | 14.5 |
60–69 | 4962 | 45.3 | 5902 | 43.4 | 3455 | 36.6 | 5142 | 40.1 | 4884 | 32.2 | 24,345 | 39.3 |
70–79 | 3033 | 27.7 | 4529 | 33.3 | 4276 | 45.2 | 5315 | 41.4 | 6828 | 45.0 | 23,981 | 38.7 |
≥ 80 | 331 | 3.0 | 530 | 3.9 | 669 | 7.1 | 821 | 6.4 | 2335 | 15.4 | 4686 | 7.6 |
Number of comorbidities (RCS Charlson score) | ||||||||||||
0 | 8690 | 79.3 | 10,672 | 78.5 | 7216 | 76.3 | 10,009 | 78.0 | 11,383 | 75.1 | 47,970 | 77.4 |
1 | 1565 | 14.3 | 1985 | 14.6 | 1531 | 16.2 | 1953 | 15.2 | 2427 | 16.0 | 9461 | 15.3 |
≥ 2 | 708 | 6.5 | 931 | 6.9 | 705 | 7.5 | 869 | 6.8 | 1355 | 8.9 | 4568 | 7.4 |
Deprivation status (national quintiles) | ||||||||||||
1 (least deprived) | 2720 | 24.8 | 3338 | 24.6 | 2243 | 23.7 | 3048 | 23.8 | 3482 | 23.0 | 14,831 | 23.9 |
2 | 2620 | 23.9 | 3093 | 22.8 | 2218 | 23.5 | 3028 | 23.6 | 3613 | 23.8 | 14,572 | 23.5 |
3 | 2249 | 20.5 | 2847 | 21.0 | 1986 | 21.0 | 2715 | 21.2 | 3231 | 21.3 | 13,028 | 21.0 |
4 | 1881 | 17.2 | 2378 | 17.5 | 1647 | 17.4 | 2198 | 17.1 | 2564 | 16.9 | 10,668 | 17.2 |
5 (most deprived) | 1493 | 13.6 | 1932 | 14.2 | 1358 | 14.4 | 1842 | 14.4 | 2275 | 15.0 | 8900 | 14.4 |
Ethnicity | ||||||||||||
White | 9441 | 92.7 | 11,887 | 92.5 | 8198 | 91.6 | 11,268 | 93.0 | 13,437 | 94.0 | 54,231 | 92.9 |
Non-white | 741 | 7.3 | 967 | 7.5 | 749 | 8.4 | 849 | 7.0 | 862 | 6.0 | 4168 | 7.1 |
Missing | 781 | 734 | 505 | 714 | 866 | 3600 | ||||||